Source: International Congress 2014 – ILDs 3
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Imeri, F. Di Marco, G. Palumbo, S. Terraneo, S. Centanni, F. Ribolla, G. F. Sferrazza Papa, G. Pellegrino, E. Rancati, E. M. Parazzini (Milan, Italy). Sporadic and TSC-related lymphangioleiomyomatosis (LAM): The experience of Ospedale San Paolo of Milan (preliminary data). Eur Respir J 2014; 44: Suppl. 58, 773

Member's Comments

No comment yet.

Related content which might interest you: Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Lymphangioleiomyomatosis in TOSCA - TuberOus SClerosis registry to increAse disease awareness Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Survival in CVD-ILD at Ege University Hospital Source: International Congress 2016 – Connective tissue disorders Year: 2016 Rare primary pulmonary tumors Source: International Congress 2015 – Thoracic oncology around the world: rare cases and local features Year: 2015 Neuroendocrine cell hyperplasia (NEHI) and NEHI Syndrome: Lung biopsy necessary? Source: International Congress 2014 – ILDs 4 Year: 2014 Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical findings at initial presentation of IPF patients at a university hospital referral center Source: International Congress 2014 – ILDs 5 Year: 2014 The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic. Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 Benefit of steroid-free treatment compared to standard therapy (ST) in pulmonary sarcoidosis Source: International Congress 2014 – ILDs 5 Year: 2014 Cystic lung disease with pulmonary amyloidosis: Analysis of 21 patients Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 LATE-BREAKING ABSTRACT: Epidemiology of IPF in Italy Source: International Congress 2014 – ILDs 6 Year: 2014 Sarcoidosisandpulmonarydust: Mineralogical analysis (MA) and optical microscopy (OM) Source: International Congress 2014 – Sarcoidosis Year: 2014 Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients Source: International Congress 2014 – Sarcoidosis Year: 2014 Does the BTNL2 genotype influence the course of disease in Danish sarcoidosis patients? Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Translation and validation of the King's brief interstitial lung disease (K-BILD) questionnaire in French, Italian and Dutch Source: International Congress 2014 – ILDs 2 Year: 2014 Pleuroparenchymal fibroelastosis (PPFE) – Resembling features in patients with malignancies Source: International Congress 2015 – IIPs: orphan Year: 2015